Adenosine and dialysis hypotension.
In this issue, Imai et al. report the results of a double-blind placebo-controlled study on the effect of an adenosine A1 receptor antagonist, FK352, on the incidence of dialysis hypotension in hypotension-prone patients. This Commentary discusses the use of selective adenosine A1 receptor antagonists for the prevention of dialysis hypotension from the perspective of the potential role of adenosine in its pathogenesis.
Franssen
C F M
CF
Dialysis Center Groningen and Department of Internal Medicine, Division of Nephrology, University Medical Centre Groningen and University of Groningen, Hanzelplein 1, 9713 CZ Groningen, the Netherlands. c.f.m.franssen@int.umcg.nl
D000241:Adenosine / Q000502:physiology*; D058916:Adenosine A1 Receptor Antagonists; D006801:Humans; D007022:Hypotension / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D008955:Models, Cardiovascular; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
D058916:Adenosine A1 Receptor Antagonists; C114384:FK 352; D011720:Pyrazoles; D011725:Pyridines; D000241:Adenosine